Диссертация (1140892), страница 26
Текст из файла (страница 26)
‒ T. 5. ‒ C. 2666.234. Afrin L. B., Khoruts A. Mast Cell Activation Disease and Microbiotic Interactions // Clin Ther. ‒2015. ‒ T. 37, № 5. ‒ C. 941-53.235. McNeil B. D., Pundir P., Meeker S., Han L., Undem B. J., Kulka M., Dong X. Identification of amast-cell-specific receptor crucial for pseudo-allergic drug reactions // Nature. ‒ 2015. ‒ T.519, № 7542. ‒ C. 237-41.236.
Horan R. F., Sheffer A. L., Austen K. F. Cromolyn sodium in the management of systemicmastocytosis // J Allergy Clin Immunol. ‒ 1990. ‒ T. 85, № 5. ‒ C. 852-5.237. Tolar J., Tope W. D., Neglia J. P. Leukotriene-receptor inhibition for the treatment of systemicmastocytosis // N Engl J Med. ‒ 2004. ‒ T. 350, № 7. ‒ C. 735-6.238. Oppong E., Flink N., Cato A. C. Molecular mechanisms of glucocorticoid action in mast cells //Mol Cell Endocrinol. ‒ 2013.
‒ T. 380, № 1-2. ‒ C. 119-26.239. Brazzelli V., Grassi S., Merante S., Grasso V., Ciccocioppo R., Bossi G., Borroni G. Narrowband UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment ofcutaneous mastocytosis: a study in 20 patients // Photodermatol Photoimmunol Photomed. ‒2016. ‒ T. 32, № 5-6. ‒ C. 238-246.240. Godt O., Proksch E., Streit V., Christophers E. Short- and long-term effectiveness of oral and bathPUVA therapy in urticaria pigmentosa and systemic mastocytosis // Dermatology.
‒ 1997. ‒ T.195, № 1. ‒ C. 35-9.241. Gobello T., Mazzanti C., Sordi D., Annessi G., Abeni D., Chinni L. M., Girolomoni G. Mediumversus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study // J Am AcadDermatol. ‒ 2003. ‒ T. 49, № 4. ‒ C. 679-84.242. Prignano F., Troiano M., Lotti T.
Cutaneous mastocytosis: successful treatment with narrowbandultraviolet B phototherapy // Clin Exp Dermatol. ‒ 2010. ‒ T. 35, № 8. ‒ C. 914-5.149243. Stern R. S., Nichols K. T., Vakeva L. H. Malignant melanoma in patients treated for psoriasiswith methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study// N Engl J Med. ‒ 1997.
‒ T. 336, № 15. ‒ C. 1041-5.244. Stern R. S., Liebman E. J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment ofpsoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study // J NatlCancer Inst. ‒ 1998. ‒ T.
90, № 17. ‒ C. 1278-84.245. Wallenfang K., Stadler R. [Association between UVA1 and PUVA bath therapy and developmentof malignant melanoma] // Hautarzt. ‒ 2001. ‒ T. 52, № 8. ‒ C. 705-7.246. Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification andmanagement // Am J Hematol. ‒ 2016. ‒ T. 91, № 11.
‒ C. 1146-1159.247. Pardanani A., Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloiddisorders // Blood. ‒ 2004. ‒ T. 104, № 7. ‒ C. 1931-9.248. Hartmann K., Wardelmann E., Ma Y., Merkelbach-Bruse S., Preussner L. M., Woolery C.,Baldus S. E., Heinicke T., Thiele J., Buettner R., Longley B. J. Novel germline mutation ofKIT associated with familial gastrointestinal stromal tumors and mastocytosis //Gastroenterology. ‒ 2005.
‒ T. 129, № 3. ‒ C. 1042-6.249. Frost M. J., Ferrao P. T., Hughes T. P., Ashman L. K. Juxtamembrane mutant V560GKit is moresensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domainmutant D816VKit is resistant // Mol Cancer Ther. ‒ 2002. ‒ T. 1, № 12. ‒ C. 1115-24.250. Akin C., Brockow K., D'Ambrosio C., Kirshenbaum A.
S., Ma Y., Longley B. J., Metcalfe D. D.Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutatedc-kit // Exp Hematol. ‒ 2003. ‒ T. 31, № 8. ‒ C. 686-92.251. Ma Y., Zeng S., Metcalfe D. D., Akin C., Dimitrijevic S., Butterfield J. H., McMahon G.,Longley B. J. The c-KIT mutation causing human mastocytosis is resistant to STI571 andother KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitorsensitivity profiles than wild-type kinases and those with regulatory-type mutations // Blood.
‒2002. ‒ T. 99, № 5. ‒ C. 1741-4.252. Vega-Ruiz A., Cortes J. E., Sever M., Manshouri T., Quintas-Cardama A., Luthra R., KantarjianH. M., Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemicmastocytosis // Leuk Res. ‒ 2009. ‒ T.
33, № 11. ‒ C. 1481-4.253. Nakagomi N., Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemicmastocytosis induces imatinib-resistant constitutive KIT activation // Lab Invest. ‒ 2007. ‒ T.87, № 4. ‒ C. 365-71.150254. Elliott M. A., Pardanani A., Li C. Y., Tefferi A. Immunophenotypic normalization of aberrantmast cells accompanies histological remission in imatinib-treated patients with eosinophiliaassociated mastocytosis // Leukemia. ‒ 2004. ‒ T.
18, № 5. ‒ C. 1027-9.255. Tefferi A., Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemicmastocytosis // Int J Hematol. ‒ 2004. ‒ T. 79, № 5. ‒ C. 441-7.256. Shah N. P., Lee F. Y., Luo R., Jiang Y., Donker M., Akin C. Dasatinib (BMS-354825) inhibitsKITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in mostpatients with systemic mastocytosis // Blood. ‒ 2006. ‒ T. 108, № 1. ‒ C.
286-91.257. Olivieri A., Manzione L. Dasatinib: a new step in molecular target therapy // Ann Oncol. ‒ 2007.‒ T. 18 Suppl 6. ‒ C. vi42-6.258. Gleixner K. V., Mayerhofer M., Cerny-Reiterer S., Hormann G., Rix U., Bennett K. L.,Hadzijusufovic E., Meyer R. A., Pickl W. F., Gotlib J., Horny H. P., Reiter A., MitterbauerHohendanner G., Superti-Furga G., Valent P. KIT-D816V-independent oncogenic signaling inneoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption bydasatinib and bosutinib // Blood.
‒ 2011. ‒ T. 118, № 7. ‒ C. 1885-98.259. Schittenhelm M. M., Shiraga S., Schroeder A., Corbin A. S., Griffith D., Lee F. Y., BokemeyerC., Deininger M. W., Druker B. J., Heinrich M. C. Dasatinib (BMS-354825), a dual SRC/ABLkinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loopmutant KIT isoforms associated with human malignancies // Cancer Res. ‒ 2006.
‒ T. 66, № 1.‒ C. 473-81.260. Lombardo L. J., Lee F. Y., Chen P., Norris D., Barrish J. C., Behnia K., Castaneda S., CorneliusL. A., Das J., Doweyko A. M., Fairchild C., Hunt J. T., Inigo I., Johnston K., Kamath A., KanD., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G. L., Schmidt R.
J., TokarskiJ., Wen M. L., Wityak J., Borzilleri R. M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinicalassays // J Med Chem. ‒ 2004. ‒ T.
47, № 27. ‒ C. 6658-61.261. Tokarski J. S., Newitt J. A., Chang C. Y., Cheng J. D., Wittekind M., Kiefer S. E., Kish K., Lee F.Y., Borzillerri R., Lombardo L. J., Xie D., Zhang Y., Klei H. E. The structure of Dasatinib(BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity againstimatinib-resistant ABL mutants // Cancer Res. ‒ 2006. ‒ T. 66, № 11. ‒ C. 5790-7.262. Verstovsek S., Tefferi A., Cortes J., O'Brien S., Garcia-Manero G., Pardanani A., Akin C., FaderlS., Manshouri T., Thomas D., Kantarjian H.
Phase II study of dasatinib in Philadelphia151chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis //Clin Cancer Res. ‒ 2008. ‒ T. 14, № 12. ‒ C. 3906-15.263. Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Casteran N., Borge L., Hajem B.,Lermet A., Sippl W., Voisset E., Arock M., Auclair C., Leventhal P. S., Mansfield C. D.,Moussy A., Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitortargeting KIT // PLoS One. ‒ 2009.
‒ T. 4, № 9. ‒ C. e7258.264. Paul C., Sans B., Suarez F., Casassus P., Barete S., Lanternier F., Grandpeix-Guyodo C., DubreuilP., Palmerini F., Mansfield C. D., Gineste P., Moussy A., Hermine O., Lortholary O. Masitinibfor the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study //Am J Hematol. ‒ 2010. ‒ T. 85, № 12. ‒ C. 921-5.265. Lortholary O., Chandesris M. O., Bulai Livideanu C., Paul C., Guillet G., Jassem E., NiedoszytkoM., Barete S., Verstovsek S., Grattan C., Damaj G., Canioni D., Fraitag S., Lhermitte L.,Georgin Lavialle S., Frenzel L., Afrin L.
B., Hanssens K., Agopian J., Gaillard R., Kinet J. P.,Auclair C., Mansfield C., Moussy A., Dubreuil P., Hermine O. Masitinib for treatment ofseverely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase3 study // Lancet. ‒ 2017. ‒ T. 389, № 10069.
‒ C. 612-620.266. Weisberg E., Manley P. W., Breitenstein W., Bruggen J., Cowan-Jacob S. W., Ray A., Huntly B.,Fabbro D., Fendrich G., Hall-Meyers E., Kung A. L., Mestan J., Daley G. Q., Callahan L.,Catley L., Cavazza C., Azam M., Neuberg D., Wright R. D., Gilliland D. G., Griffin J. D.Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl // CancerCell. ‒ 2005.
‒ T. 7, № 2. ‒ C. 129-41.267. Hochhaus A., Baccarani M., Giles F. J., le Coutre P. D., Muller M. C., Reiter A., SantanastasioH., Leung M., Novick S., Kantarjian H. M. Nilotinib in patients with systemic mastocytosis:analysis of the phase 2, open-label, single-arm nilotinib registration study // J Cancer Res ClinOncol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
